Podcasts about cancer treatment

This interview is disseminated on behalf of GT Biopharma. GT Biopharma (NASDAQ: GTBP) recently received approval from the U.S. Food and Drug Administration (FDA) for a new investigational drug trial for the solid tumor cancer treatment GTB-3650, as the race to develop a cure for cancer intensifies and the solid tumor market grows to $362 billion.Executive Chairman and Chief Executive Officer Michael Breen shares more details about the company's expectations and success indicators for the basket trial of the new medication, as well as upcoming milestones for 2026.Explore GT Biopharma: https://www.gtbiopharma.com/Watch the full YouTube interview here: https://youtu.be/VtISaFICJ5gAnd follow us to stay updated: https://www.youtube.com/GlobalOneMedia

BUFFALO, NY – February 25, 2026 – A new #editorial perspective was #published in Volume 17 of Oncotarget on February 20, 2026, titled “CAR-T therapy: Trailblazing CAR(ing) in cancer treatment.” Led by Uzma Saqib — with corresponding author Krishnan Hajela from the School of Life Sciences, Devi Ahilya Vishwavidyalaya — the perspective reviews recent clinical and translational advances in chimeric antigen receptor T-cell (CAR-T) therapy and highlights both its promise and its remaining barriers. The piece synthesizes recent clinical advances in hematologic malignancies and emerging applications in solid tumors, while focusing attention on safety (for example, cytokine release syndrome and neurotoxicity), resistance, antigen specificity, and access disparities. The authors summarize the CAR-T workflow (leukapheresis → genetic modification and expansion → infusion) and note major recent clinical gains — including improved outcomes in leukemia, lymphoma, and multiple myeloma — that support wider adoption of cellular immunotherapy approaches. They emphasize that despite these advances, important clinical challenges remain, particularly for solid tumors, where antigen selection, tumor microenvironment, and T-cell trafficking limit efficacy. At the same time, the perspective highlights technological and clinical strategies under development to overcome these obstacles, including next-generation CAR designs and improved supportive-care protocols. “Despite its promise, CAR T-cell therapy faces several critical challenges.” The authors call out clear next steps for the field: (1) continued refinement of CAR constructs (dual-targeting, switchable/on-off systems, armored CARs) to improve specificity and reduce on-target/off-tumor toxicity; (2) improved management protocols and prophylactic measures to mitigate CRS and neurotoxicity; (3) expanded investigation of allogeneic or alternative CAR-T platforms to address manufacturing, cost, and access barriers; and (4) focused translational studies to improve T-cell trafficking and efficacy in solid tumors. They also highlight equity issues — socioeconomic and racial disparities that limit access to CAR-T — and urge that broad deployment plans include strategies to expand availability and affordability. DOI - https://doi.org/10.18632/oncotarget.28836 Correspondence to - Krishnan Hajela - hajelak@gmail.com Abstract video - https://www.youtube.com/watch?v=T4hbwPToVKI Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28836 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, CAR-T therapy, therapeutic approaches To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

A humble stripey fish could be key to treating a chronic & painful swelling condition that's a common side effect of some breast cancer treatment. Lymphoedema usually affects the arms or legs and can be caused by cancer treatments that remove or damage the lymph nodes. Auckland University scientists have discovered a molecule in Zebrafish larva that offers hope of a treatment. Lead researcher, Dr Jonathan Astin spoke to Lisa Owen.

Interview with Gennady Bratslavsky, MD, and Hanan Goldberg, MD,

We would love to hear from you! Please share your thoughts or episode ideas at ⁠⁠⁠⁠canceroutloud@cancercare.org⁠⁠⁠⁠ or leave a comment on this episode!Please follow, rate and share Cancer Out Loud to help others find strength and support through our community.SummaryIn this episode of Cancer Out Loud, CancerCare social worker Christina Monaco and Alexa Dashko, an Oncology Dietitian, discuss the vital role of nutrition in cancer care. They explore the emotional aspects of dietary choices, common misconceptions about food and cancer, and the importance of setting boundaries during treatment. The conversation also addresses food access issues, cultural considerations in nutrition, and the significance of community support. Listeners are encouraged to seek help from dietitians and to prioritize their own needs during their cancer journey.TakeawaysNutrition impacts emotional and mental health during cancer treatment.Patients often feel overwhelmed by dietary advice and need clear guidance.Setting boundaries with family during meals is crucial for comfort.Common misconceptions about diet can lead to unnecessary stress for patients.Food access issues can significantly affect a patient's ability to maintain nutrition.Cultural preferences should be respected in dietary recommendations.Patients should feel empowered to advocate for their nutritional needs.Community support plays a vital role in a patient's journey.Dietitians are accessible resources for cancer patients.It's important to focus on what patients can eat rather than what they can't.

Don't be surprised if you find yourself needing head and neck cancer surgery and your surgeon has an unexpected assistant: a robot. But it won't be R2D2 or C3P0 from Star Wars. Instead, the modern medical robot is a high-tech tool that surgeons use to perform sensitive tasks in hard-to-reach places. In this episode, Dr. Vivian Wu, a head and neck surgeon at Pacific Neuroscience Institute, takes us into the new world of robotic surgeries. Dr. Wu also tells us about some new tests that can show how successful someone's cancer treatment has been, without the need for invasive biopsies. She talks about how to prevent and treat Human Papillomavirus, or HPV, which has started showing up in people's mouths in greater numbers. Dr. Wu also emphasizes the important role a care “village” plays in a patient's treatment and recovery.

Dr. Vernon Sondak discusses alternatives for non-surgical candidates with skin cancer, including systemic therapy.

Science communicator and bat expert Dan Riskin talks to Andrew Carter every Wednesday at 8:20.

What if the biggest obstacle to your healing isn't your diagnosis... but the fact that you were never taught you had a choice?From the time we're young, we're conditioned to follow the rules, trust the experts, and do what we're told. And when it comes to your health, that conditioning kicks into overdrive. Dr. Katie Deming opens up about why so many people hand over their power the moment they walk into a doctor's office, and what it actually costs them. As a radiation oncologist who walked away from the system, she's seen both sides of this story firsthand.This kicks off a brand new series on reclaiming your authority. Dr. Katie explores the hidden forces that keep you from speaking up for yourself, including the pressure from well-meaning family, the fear of being labeled "non-compliant," and the people-pleasing patterns that run deeper than most of us realize. She also shares her own turning point, the moment a simple parable changed everything about how she saw her career and the medical system she'd spent her life in.Chapters: 00:03:00 - The Illusion of One Right Way to Heal00:06:00 - Your Values Determine Your Healing Path00:11:00 - When Survival Conflicts with Meaning00:15:00 - The Cost of Following Your Truth00:19:00 - How We're Conditioned to Hand Over Our Power00:23:00 - Reclaiming Authority Without Rejecting Guidance00:26:00 - Healing as Growth Not a Single DestinationLearn the difference between following a path and actually choosing one. Dr. Katie breaks down why your values matter more than any protocol and why healing isn't a single destination you arrive at. It's a practice you return to every single day.Stay until the end to hear the one question Dr. Katie believes matters more than "what should I do" and why the answer could reshape every health decision you make from here on out.Press play and learn how to stop outsourcing your power and start becoming the author of your own healing journey.Access the FREE Water Fasting Masterclass Now: https://www.katiedeming.com/the-healing-power-of-fasting/ Transform your hydration with the system that delivers filtered, mineralized, and structured water all in one. Spring Aqua System: https://springaqua.info/drkatieDownload the FREE Healing Tools Guide: https://bit.ly/drkatie-giftguide MORE FROM KATIE DEMING M.D. Work with Dr. Katie: www.katiedeming.com 6 Pillars of Healing Cancer Workshop Series - Click Here to Enroll Follow Dr. Katie Deming on Instagram: https://www.instagram.com/katiedemingmd/ Email: INFO@KATIEDEMING.COM Please Support the Show Share this episode with friends & family Give a Review on Spotify Give a Review on Apple Podcast Watch on Youtube: https://youtube.com/playlist?list=PL5LplU70TE9i01tW_7Tozi8b6X6rGBKA2&si=ZXLy5PjM7daD6AV5 DISCLAIMER: The Born to Heal Podcast is intended for informational purposes only and is not a substitute for seeking professional medical advice, diagnosis, or treatment. Individual medical histories are unique; therefore, this episode should not ...

This Biotech Stock Is Disrupting Cancer Treatment - Meet Raphi Levy, CFO, Alpha Tau $DRTSGuest Raphi Levy, CFO, Alpha Tau Company Alpha TauTicker: $DRTSWebsite https://www.alphatau.com Raphi's BioRaphi Levy has served as our Chief Financial Officer since 2019. Prior to joining us, Mr. Levy served in the Investment Banking Division at Goldman Sachs from 2006 until 2019 in New York and Tel Aviv, most recently serving as Executive Director in charge of healthcare banking in Israel.Mr. Levy has served as a director of MX Management LP since April 2022. Mr. Levy holds a B.S. in Economics from the Wharton School of Business, University of Pennsylvania, and a B.S.E. and M.S.E. in Electrical Engineering from the School of Engineering and Applied Science, University of Pennsylvania. Company BioAbout Alpha Tau Medical Ltd. Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.

Episode 179 hosts Faye Holland and James Parton sit down with Irina Barbina (CEO) and Matthew Griffiths (CTO) to unpick how Concr is using predictive modelling and digital twins to transform cancer drug development.Cancer data is fragmented. Clinical trials, pre-clinical research, and real-world patient data exist in silos. There's no unified way to predict how individual patients will respond to specific therapies, until now.Concr's technology borrows from astrophysics, specifically, how scientists model dark matter using gravitational lensing. The parallel is striking: Astrophysicists can't directly observe dark matter, so they build complex simulations to infer its distribution. Concr can't directly know why a drug worked for a patient, so they build digital twin simulations to predict outcomes.Key innovations:· Bayesian inference at scale to handle messy, incomplete cancer data· Hierarchical modelling that learns from shared biology across cancer types· 94% prediction accuracy on retrospective clinical trial data· Prospective validation underway with NHS partners and pharma companiesConcr dramatically reduces the cost and complexity of clinical trials. This episode brilliantly illustrates why Cambridge is a global innovation hub. It's not just about brilliant science, it's about brilliant people from different disciplines colliding, recognising patterns, and building companies that matter. Hosted on Acast. See acast.com/privacy for more information.

A better approach to cancer. https://www.oasisofhope.com/ b17works.comChurch and State is brought to you by, YOU!Visit us at: https://churchandstate.media, where you can support us by donating directly and find links to shop with our affiliates.Get our merch at https://standupnowapparel.com/partner-church-and-state/Learn how to Protect Your Wealth against inflation at: www.BH-PM.com and tell them Church and State sent you.Support Church and State today by shopping at www.MyPillow.com using our coupon code: “CHURCHANDSTATE”.Our links are on link tree: https://linktr.ee/churchandstateSubscribe to our Locals Community (churchandstate1.locals.com)Follow us on Rumble (@ChurchandState1776) https://rumble.com/user/ChurchandState1776X(twitter) (@1churchandstate) https://x.com/1churchandstatefacebook (churchandstate1776) https://www.facebook.com/ChurchandState1776SubStack (churchandstate.substack.com) https://churchandstate.substack.com/*Help fund our fight against tyranny: Buy from our affiliates and tell them Church and State sent you.*Tune in on NRBTV Tue-Fri 1:30 PM Pacific!Become a supporter of this podcast: https://www.spreaker.com/podcast/prepper-broadcasting-network--3295097/support.BECOME A SUPPORTER FOR AD FREE PODCASTS, EARLY ACCESS & TONS OF MEMBERS ONLY CONTENT!Red Beacon Ready OUR PREPAREDNESS SHOPThe Prepper's Medical Handbook Build Your Medical Cache – Welcome PBN FamilySupport PBN with a Donation Join the Prepper Broadcasting Network for expert insights on #Survival, #Prepping, #SelfReliance, #OffGridLiving, #Homesteading, #Homestead building, #SelfSufficiency, #Permaculture, #OffGrid solutions, and #SHTF preparedness. With diverse hosts and shows, get practical tips to thrive independently – subscribe now!Newsletter – Welcome PBN FamilyGet Your Free Copy of 50 MUST READ BOOKS TO SURVIVE DOOMSDAY

Roger Stone interviews Dr. Patrick Soon-Shiong, a prominent surgeon and entrepreneur, regarding a breakthrough cancer treatment called Anktiva. Dr. Patrick explains that the drug utilizes a molecule known as IL-15, which was identified by health authorities years ago as the top potential cure for cancer due to its ability to stimulate the body's natural immune cells. Despite its efficacy in treating bladder cancer and reversing lymphopenia, a condition linked to early death, the doctor argues that bureaucratic hurdles at the FDA are preventing the drug's widespread use for other terminal illnesses. The discussion concludes with a call for presidential intervention to bypass regulatory stagnation, ensuring that American medical innovations can save lives at home rather than being led primarily by foreign nations. Learn more about your ad choices. Visit megaphone.fm/adchoices

On this episode host Jonathan Chance talks with Michael Krachon of Theragenics about the future of prostate cancer treatment. Jonathan and Michael talk about.·       Researching prostate cancer treatment options before meeting with your doctor.·       What is LDR brachytherapy for treating prostate cancer.·       The current need to increase awareness about LDR brachytherapy.·       How Theragenics is helping drive the future of isotope-based cancer treatments?·       What newly diagnosed prostate cancer patient should know about treatment options.For more information about brachytherapy and prostate cancer, visit Theragenics website at: LifeAfterSeeds.com  Prostate Cancer Aware is grateful to the Jevan and Ruzanna Chimayan Foundation for their generous donation, which will help fuel our podcast and website to raise critical awareness about prostate cancer and the PSA test around the world.Prostate Cancer Aware is a copyrighted production. No content maybe rebroadcast or reproduced without the expressed written consent of the Friedman Sidrow Foundation. For more information about prostate cancer, the PSA test, men's health and Jonathan's inspiring new book Unaware, which is about his battle with prostate cancer. Visit our website at: https://www.iknowmypsa.org Email us at: https://www.iknowmypsa.org/contactus/ Follow Prostate Cancer Aware on social media at: Facebook - https://www.facebook.com/iknowmypsa Twitter - https://twitter.com/iknowmypsa or @iknowmypsa Thank you for listening! Remember, Stay Aware and Stay Healthy.™

Artificial lungs kept a man alive until he could get a transplant A simple shift in schedule could make cancer immunotherapy work better Contact the Show: coolstuffdailypodcast@gmail.com Learn more about your ad choices. Visit megaphone.fm/adchoices

A cancer diagnosis can be devastating. And the chemotherapy that often follows can be particularly rigorous. The American Cancer Society projects that 2.1 million people in the United States will be diagnosed with cancer in 2026—but researchers are making major advances in cancer treatment and patient survival. Ziyang Zhang is a chemist and 2023 Pew-Stewart Scholar for Cancer Research who leads cutting-edge studies on reducing the negative effects of chemotherapy on cancer patients. In his lab at the University of California, Berkeley, he and his team are producing new tools at the chemical level that will help to develop more effective therapies to target cancer mutations and avoid damage to healthy cells.

A Kansas school community rallies to support a beloved teacher fighting cancer after his car is stolen while he is away for treatment. A New Jersey teacher is sentenced to prison after a sexual abuse case involving two students reveals she became pregnant by one teen she groomed and later terminated the pregnancy. Drew Nelson reports. See omnystudio.com/listener for privacy information.

Guest Full Name: Dr. R. Stacy Lindborg, PhDGuest Title: President, Chief Executive Officer, and Board DirectorCompany: IMUNONTicker: IMNNWebsite: https://imunon.com/Guest Bio:Stacy R. Lindborg, PhD, was appointed President and Chief Executive Officer of IMUNON in May 2024. Dr. Lindborg has served on IMUNON's Board of Directors since June 2021. She has nearly 30 years of experience in the pharmaceutical and biotech industries, with a particular focus on R&D, regulatory affairs, executive management, and strategy development. She has designed, hired, and led global teams, guiding long-term visions for growth through analytics and stimulating innovative development platforms to increase productivity.Prior to joining IMUNON, Dr. Lindborg was Executive Vice President and Co-Chief Executive Officer at BrainStorm Cell Therapeutics, where she remains a member of the company's Board of Directors. At BrainStorm, she was accountable for creating and executing clinical development strategies through registration and launch and progressed its novel cell therapy for ALS through a positive Phase 3 Special Protocol Assessment (SPA) study with the U.S. Food and Drug Administration. She frequently interacted with investors and analysts, represented the company in the scientific community and with the media, and played an active role in discussions with potential business partners.Dr. Lindborg previously was Vice President and Head of Global Analytics and Data Sciences, responsible for R&D and marketed products at Biogen. She began her biopharmaceutical career at Eli Lilly and Company, where, over the course of 16 years, she assumed positions of increasing responsibility, including Head of R&D strategy.Dr. Lindborg received an MA and PhD in statistics, and a BA in psychology and math from Baylor University. She has authored more than 200 presentations and 90 manuscripts that have been published in peer-reviewed journals, including 20 first-authored. She has held numerous positions within the International Biometric Society and American Statistical Association and was elected Fellow in 2008.Company Bio:IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of diseases. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response.IMUNON's lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer. IMNN-001 is the first therapy to achieve a clinically effective response in advanced (stage IIIC/IV) ovarian cancer including benefits in both progression-free survival (PFS) and overall survival (OS) in a first-line treatment setting when used with standard of care chemotherapy. IMUNON has completed multiple clinical trials evaluating the potential of IMNN-001, including one Phase 2 clinical trial (OVATION 2), and is currently conducting a Phase 3 clinical trial (OVATION 3). The first patient was dosed in the Phase 3 study in the third quarter of 2025. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as IL-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

A kiwi cancer patient forced to move to Australia to get life prolonging drugs, that are not funded in Aoteaora is giving a big thank you to the country. In New Zealand she was draining her savings and paying $133,000 a year for the drug daratumumab or dara; in Australia it is costing her nothing. Nic Vipond spoke to Lisa Owen.

Brachytherapy is an inside-out radiation approach to treating tumors that may offer advantages over external beam radiation in some situations. Samuel Marcrom, M.D., a radiation oncologist, discusses how brachytherapy differs from external beam radiation including its situational advantages and challenges, as well as common uses. He explains patient selection, treatment logistics, and the UAB patient experience.

In this episode of Denatured, Jennifer C. Smith-Parker speaks with Dr. Rob Monroe, Vice President and Chief Scientific Officer of Oncology at Danaher Corporation and Chief Medical Officer at Leica Biosystems, and Jennifer Fakish, Vice President and Franchise Head of Oncology at Danaher Corporation. We'll be discussing how antibody drug conjugates (ADCs) are transforming cancer care and with AI-powered pathology, doctors can now measure her HER2 more precisely to match patients with the best treatments. HostJennifer Smith-Parker, Director of Insights, BioSpaceGuestsDr. Rob Monroe, Vice President and Chief Scientific Officer, Oncology, Danaher Corporation; Chief Medical Officer, Leica BiosystemsJennifer Faikish, Vice President and Franchise Head, Oncology, Danaher CorporationDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

How do breakthroughs in the lab become real-world treatments that save lives? In this episode, Professor Stephen Maher of Trinity College Dublin joins us to discuss the rapidly evolving field of translational oncology and how cutting-edge research is shaping the future of cancer therapy. As a leading expert in radiation research and Director of Postgraduate Studies for the School of Medicine at Trinity, Stephen focuses on a critical question: why do some cancers respond to treatment while others resist it? His work examines the role of microRNAs, tumor hypoxia, and DNA damage response in shaping how cancers react to chemotherapy and radiotherapy — with particular attention to oesophageal and pancreatic cancers. In this episode, we explore: ·       Where anti-cancer therapeutics are headed in the coming years ·       How radiation research is evolving to improve treatment precision ·       Why translational oncology is essential for turning discovery into patient care ·       How treatment resistance forms — and what researchers are doing to overcome it After earning his Ph.D. in Oncology at RCSI and completing a fellowship at the National Cancer Institute in Maryland, Professor Maher has dedicated his career to bridging the gap between scientific discovery and clinical impact. He leads major national and international collaborations and has helped build advanced radiotherapy and hypoxia research programs at Trinity's Translational Medicine Institute. Learn more about Professor Maher and his work here. Episode also available on Apple Podcasts: https://apple.co/38oMlMr 

Low-dose naltrexone (LDN) is highlighted as a supportive treatment in oncology, enhancing other therapies rather than acting alone. It helps regulate the immune system, calms microglia, and alleviates symptoms like pain and fatigue. LDN's low toxicity and potential to improve quality of life are emphasized, along with its evolving role in cancer therapies and immune modulation.

A diagnosis and even aggressive treatment does not have to mark the end of strength, intimacy, or confidence. In this episode, Dr. Stephen Petteruti speaks directly to men navigating erectile dysfunction, low testosterone, and Peyronie's disease after prostate cancer treatment, reframing recovery around vitality rather than fear. He challenges the idea that sacrificing sexual health is the price of survival and explains why health span and sex span matter as much as lifespan. With a focus on regeneration and informed decision-making, Dr. Stephen outlines how carefully managed testosterone support, vascular health strategies, and tissue-preserving approaches can help men restore energy and sexual function. The discussion emphasizes critical thinking, patient autonomy, and the importance of treating men, not just lab numbers.Question the assumptions you've been given and decide how fully you want to live moving forward. Watch the episode of ED, Low Testosterone and Peyronie's After Prostate Cancer Treatment.Enjoy the podcast? Subscribe and leave a 5-star review.Dr. Stephen Petteruti is a leading Functional Medicine Physician dedicated to enhancing vitality by addressing health at a cellular level. Combining the best of conventional medicine with advancements in cellular biology, he offers a patient-centered approach through his practice, Intellectual Medicine 120. A seasoned speaker and educator, he has lectured at prestigious conferences like A4M and ACAM, sharing his expertise on anti-aging. His innovative methods include concierge medicine and non-invasive anti-aging treatments, empowering patients to live longer, healthier lives.Website: https://www.drstephenpetteruti.com/ Practice: www.intellectualmedicine.com YouTube: https://www.youtube.com/@intellectualmedicine LinkedIn: https://www.linkedin.com/in/drstephenpetteruti/ Instagram: https://www.instagram.com/dr.stephenpetteruti/ Facebook: https://www.facebook.com/dr.stephenpetteruti    Disclaimer:  The content presented in this video reflects the opinions and clinical experience of Dr. Stephen Petteruti and is intended for informational and educational purposes only. It is not medical advice and should not be used as a substitute for professional diagnosis, treatment, or guidance from your personal healthcare provider. Always consult your physician or qualified healthcare professional before making any changes to your health regimen or treatment plan.Produced by https://www.BroadcastYourAuthority.com 

Cardio-Oncology: Keeping the Heart Healthy During Cancer Treatment February 8, 2026 Yale Cancer Center visit: https://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

Watch the FULL podcast here: https://youtu.be/yZDzsfNjG_MCurious what Akkermansia actually does for your health? It's discussed here as a keystone gut microbe linked to improved insulin sensitivity, lower A1C in clinical studies, GLP-1 release and healthier blood vessels, with associations to cancer immunotherapy response. This clip explores the gut brain circulation connection, how metabolism and energy relate to this microbe, and why people considering immunotherapy might also focus on gut health. We also touch on the importance of discussing immunotherapy with an oncologist and staying within medical advice boundaries. ***This episode is sponsored by:NOWATCH: The compassionate health trackerConnecting body and mind with unique stress recovery insights so you can live fully today15% off with code LWBW15 at https://nowatch.com/Mojo: the app for expert-led courses in better sex.Learn from world-class sex therapists and relationship experts with courses tailored to your needs.15% off with code LiveWell15 at mymojo.com/livewellbewell***The Great British Veg OutHow to support your gut, energy, and hormones by eating more — not less.

In this episode of Genetics in Your World, GSA Early Career Scientist Multimedia Subcommittee advisor Sarah Renee Phillips interviews Srishti Patil of the German Cancer Research Center and Dr. Robert Noble of City St. George's, University of London about their research. Read their paper titled, “Preventing evolutionary rescue in cancer using two-strike therapy,” published in the February 2026 issue of GENETICS: https://doi.org/10.1093/genetics/iyaf255.Music: Loopster Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 License, http://creativecommons.org/licenses/by/3.0/#evolution #cancer #GeneticRescue #variation #selection #mutation Hosted on Acast. See acast.com/privacy for more information.

This episode of the Physics World Weekly podcast features Todd McNutt, who is a medical physicist at Johns Hopkins University and the founder of Oncospace. In a conversation with Physics World's Tami Freeman, McNutt explains how an artificial intelligence-based tool called Plan AI can help improve the quality of radiation therapy plans for cancer treatments. As well as discussing the benefits that Plan AI brings to radiotherapy patients and cancer treatment centres, they examine its evolution from an idea developed by an academic collaboration to a clinical product offered today by Sun Nuclear, a US manufacturer of radiation equipment and software. This podcast is sponsored by Sun Nuclear.

Megan's story begins with complications in a wanted pregnancy leading to a life-threatening molar pregnancy diagnosis. A molar pregnancy happens when what should be placenta/baby/pregnancy tissue grows abnormally instead, creating cancerous cells.For Megan, this meant facing something she never thought would come from pregnancy: becoming a cancer patient. She found herself not only grieving the loss of her pregnancy but also having to do cancer treatments to save her own life.Listen in to hear the raw reality of making medical pregnancy decisions under crisis conditions. If you've felt isolated during fertility and pregnancy health crises (that are just never talked about!)… if you wonder how to survive grieving a pregnancy that needed heartbreaking medical interventions …. if you had to make impossible choices for your body/pregnancy… this episode is for you.CONNECT WITH MEGAN TENNIS:@meganmiscarried on TikTokMegan is also a licensed clinical professional counselor in Illinois: https://www.advancedbhs.com/megan-tennis-lpc/ and she wants to share the link for the helpful non-profit organization Chasing The Rainbows: https://linktr.ee/chasingtherainbowsTFMR GRIEF CIRCLE PROGRAM STARTING IN FEB. 2026:If you're longing for intimate, ongoing group support, apply now for the Ascend TFMR Grief Circle

In this episode, UROONCO PCa Associate Editor Assoc. Prof. Pawel Rajwa (PL) interviews medical oncologist Prof. Silke Gillessen Sommer (CH) about the present and future directions of metastatic prostate cancer treatment.They discuss the greatest survival gains in metastatic prostate cancer over the past decade, triplet therapy in mHSPC and patient selection, the role of PSMA-PET imaging and sequencing of systemic therapies in metastatic prostate cancer, biomarker-driven treatment selection, and finally where the future of metastatic prostate cancer treatment is heading.Here are the links to the articles and event which were mentioned in this podcast: EORTC GUCG 2238 De-escalate trialCAPItello-281 phase III studyAPCCC (Advanced Prostate Cancer Consensus Conference)For more updates on prostate cancer, please visit our educational platform UROONCO PCa.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

Shaun Bagai is the CEO and Director of RenovoRx, and a seasoned MedTech leader whose path began with a Silicon Valley startup internship that ultimately pulled him away from medical school and into building life-changing technologies. Shaun shares how early experiences in clinical research, physician training, and commercialization—from Medtronic to multiple high-growth startups—shaped his leadership philosophy around mentorship, hiring for “fit,” and balancing empowerment with accountability. Shaun reflects on legacy, values-driven leadership, and why networking rooted in genuine curiosity can become one of the most powerful tools in a MedTech career. Guest links: https://renovorx.com/contact-us/ | https://www.linkedin.com/in/shaun-r-bagai/   Charity supported: ASPCA Interested in being a guest on the show or have feedback to share? Email us at theleadingdifference@velentium.com.  PRODUCTION CREDITS Host & Editor: Lindsey Dinneen Producer: Velentium Medical   EPISODE TRANSCRIPT Episode 072 - Shaun Bagai [00:00:00] Lindsey Dinneen: Hi, I'm Lindsey and I'm talking with MedTech industry leaders on how they change lives for a better world. [00:00:09] Diane Bouis: The inventions and technologies are fascinating and so are the people who work with them. [00:00:15] Frank Jaskulke: There was a period of time where I realized, fundamentally, my job was to go hang out with really smart people that are saving lives and then do work that would help them save more lives. [00:00:28] Diane Bouis: I got into the business to save lives and it is incredibly motivating to work with people who are in that same business, saving or improving lives. [00:00:38] Duane Mancini: What better industry than where I get to wake up every day and just save people's lives. [00:00:42] Lindsey Dinneen: These are extraordinary people doing extraordinary work, and this is The Leading Difference. Hello, and welcome back to another episode of The Leading Difference podcast. I'm your host, Lindsey, and today I am delighted to introduce you to my guest, Sean Bagai. Sean has served as Chief Executive Officer and Director since 2014 of RenovoRx. Prior to joining, he led global market development for HeartFlow, Inc from 2011 to 2014, which included directing Japanese market research, regulatory payer collaboration, and key opinion leader development to create value, resulting in a company investment to form HeartFlow Japan. During his tenure at HeartFlow, he successfully orchestrated their largest clinical trial to date and contracted HeartFlow's first global customers. In addition, Sean has launched innovative technologies into regional and global marketplaces in both large corporations and growth phase novel technology companies. Sean is a graduate from the University of California Santa Barbara with a Bachelor of Science in Biology / Pre-med. All right. Well, thank you so much for being here, Sean. I'm so delighted to speak with you today. [00:01:54] Shaun Bagai: Thanks for the opportunity. I really appreciate it. [00:01:55] Lindsey Dinneen: Of course. Well, I'd love, if you wouldn't mind starting off by just telling us a little bit about who you are, what your background has been like, and what led you to MedTech? [00:02:07] Shaun Bagai: I really appreciate the question 'cause it's really my background and kinda the early part of my journey that landed me where I am today. I actually did an internship at a medical device startup company in Silicon Valley between what would've been college and med school. And while I was applying to med school, my goal was to get some experience in the industry, in a medical technology space, and then go out to med school. And the founder of my company and CEO really advised me not to go to med school once I got in to become, someday an entrepreneur like his own self. And I ended up following his footsteps with the goal of, just like he, did build companies that really make a major impact on medicine. [00:02:44] Lindsey Dinneen: Wow. [00:02:45] Shaun Bagai: So from, yeah, so from that early kind of intro to medical technology and learning what an entrepreneur could do in building new therapies and technologies, I ended up running clinical research at that company once I declined med school. We exited to Medtronic where I learned the sales side of things. So, this physician founder CEO along with my mentor, said, look, if you want to build and run companies, you have to really understand what the market's like and how you get a product into the hands of physicians to treat patients and what it takes to really sell the product. So I spent a couple years flying around the country training physicians on the technology that I learned as a proctor-- which I've done in every company that I've worked with and for-- then went on to sales for about five years and launched Medtronic's first drug coated coronary stent as a sales representative. And then transitioned out of Medtronic after several years, cutting my teeth on the big company dynamics and the sales revenue aspect of it to a startup company called Ardian, which developed a new way to treat high blood pressure using a device. There I led physician training, transitioned them from clinical research into commercial in Europe. We exited to Medtronic for about a billion dollars and went on to another startup company to help develop their market. And really that was a disruptive technology in how to assess coronary artery disease in leading international market development. They hired me about 15 years prematurely to commercialize them, so I helped them with physician training, market development in Japan, clinical research and left to join RenovoRx where I took over 11 and a half years ago. That company actually went public for about 2.5 billion this last year. So, and all three of these technologies have really already made a major impact on patients, and I feel that RenovoRx, this has probably my biggest one yet in terms of major impact. [00:04:26] Lindsey Dinneen: Yeah. Okay. So I can't wait to dive into that, but there's a lot before that too to talk about. So, when you were growing up, was medicine and science always a huge interest to you or did that develop later on? [00:04:41] Shaun Bagai: You know, it's funny you asked 'cause I've done a lot of interviews and that question has never come up. So I've gotta, I've gotta pause for a second. It's interesting. My, my background was really business oriented growing up. I loved business. I loved the idea of how you get something marketable. As a very young child, I had very embarrassing stories of trying to sell things as a kid that I used to bring back from India, for example, like bouncy balls or crocheted place mats or whatnot. But then sustaining a football injury in high school, I found that physicians couldn't treat me. And I learned that there's gotta be a different way to treat patients. And I arrogantly thought, "Well, I could be a better doctor than you guys and someday treat young athletes like myself." So, my passion went immediately and complete a hundred percent into become a physician to help patients. So that kind of transitioned me to being med school bound from the age of about 15, and didn't look back until I got into med school and got pushed back to business. And now I get the best of both worlds. [00:05:37] Lindsey Dinneen: Yeah, no, absolutely. So you have so many diverse experiences with a bunch of different companies and you know, everything from it sounds like a quite the small team to obviously these huge enterprise type companies. What are some of the key lessons you learned along the way that help you in your current role? [00:05:58] Shaun Bagai: I think the biggest aspect I've learned along the way, and what I'd definitely tell the younger entrepreneurs, is to be very open and receptive to different ideas. Also look for mentorship and leadership examples. And I've been lucky throughout my career, I've been able to identify leaders who are not perfect because no one is, but I found skill sets and activities and thought processes that I wanted to emulate, and I feel like I've been successful because I've been able to take the best of those and also look for mistakes and weaknesses and to see how I could either surround myself with people to fulfill my lack of strengths in areas and or improve on myself to help be a better leader by emulating them. [00:06:37] Lindsey Dinneen: Yeah. And speaking of leadership, as you kind of grew into all of these, you know, more and more responsibility laden roles, were there any moments along the way where you kind of just had these learning curves of, you know, either witnessing something that you were like, "Oof, I don't wanna do that." Or the opposite of it sounds like you had maybe some really great mentors in your life that showed you perhaps a better way of doing things. But in terms of your overall leadership strategy, how did the various good, bad, and ugly shape how you show up as a leader? [00:07:16] Shaun Bagai: You know, that's a four hour discussion probably, but, but to, to tackle some of the high notes that I learned, it's --and I continue to always learn-- the biggest challenge we face as leaders is trying to find out what makes people work in the right fit for your organization. And as, as you mentioned aptly, I've worked for very large and small teams, big companies, small companies, and not everyone's fit for those positions. You have very talented, enthusiastic, passionate people that could really flourish in a big company structured environment and would die in a startup company. And vice versa. You have very structured people that cannot understand the idea of progress ahead of process in small companies as well, and finding that balance of trying to get the best out of what someone likes to do and what their fit is. And further really identifying if you can align their passions and their career goals, what the company's goal is, you find the dynamite employee. So I try to find that balance has been difficult and challenging. My biggest challenge I think, in learning curve for me was trying to have both the non micromanaging skillset and then also the oversight and ability to let people run and to be successful and grow and learn and make mistakes. And then teach them from the mistakes, they'll become stronger leaders under you as well. [00:08:32] Lindsey Dinneen: Yeah. Yeah, absolutely. All right, well, bringing us to the present day, what does your company do? What are the innovative solutions that you're providing? Because I know you are on the cutting edge of a lot of really amazing technology. [00:08:48] Shaun Bagai: Yeah, it's been very exciting. We are finding a different way to treat cancer patients, and if you think about therapeutics in general, we as a medical industry and society have really looked at, "Okay, how do we kill a tumor? How do we prolong life?" And a lot of times we forget that there's a patient that's harboring that tumor and maybe the life isn't really worth it when you beat them up with chemotherapy every day and they're on a couch, not eating, not spending time with family. And what we've developed invented and really built out now commercial with a clinical research program as well, is how to localize therapies such that you don't have the systemic toxicities, but you do have the effect for patients live longer. And tumors that really don't behave well when it comes to cancer therapy, like pancreatic cancer is where we spent the bulk of our time so far. [00:09:31] Lindsey Dinneen: Okay. And then can you talk a little bit more about what makes your approach so innovative? [00:09:39] Shaun Bagai: It's really by accident like most great medical are. It's a physician who had an idea based off a single patient where he saw a challenge. And Dr. Ramtin Agah, the founder of the company, had a pancreatic cancer patient, and as a cardiologist his cardiac patient had pancreatic cancer and had a bleeder. And he scrubbed in with a radiologist to treat the bleeder and found that there's no good device to isolate segments around the pancreas because of the way the anatomy is. So what differentiates us is it was after an unmet need first, and then came the device technology and then clinical data, and now adoption where tumors like pancreatic cancer tumors don't have high blood flows posing them not susceptible to chemotherapy and not a good target for local delivery. So he developed and invented this therapy and technology to really get high doses of chemotherapy in these types of tumors in a manner and mechanism that's very different than we've ever seen before. And that's looks like it's being successful. [00:10:34] Lindsey Dinneen: Wow, that's amazing. So you have had some clinical validations, clinical trials as well? Yeah? [00:10:41] Shaun Bagai: Yeah, we did. Yeah, for sure. We did a phase one two trial initially in pancreatic cancer, non-metastatic. We found that patients that are expected to live between 12 and 20 months, let's say, or even narrower these days, about 14, 15, 16 months-- our patients were living over two and a half years and we were starting to push survival where many patients were 3, 4, 5 years since diagnosis. Since then, we've launched a phase three trial based on that, and that's wrapping up enrollment soon. And based on the success of the therapy and technology in terms of toxicities, a lot of physicians have said, look, we want to treat patients today with this. And given that the device is FDA cleared, we've now begun to commercialize the device component for physicians to use at their discretion, where we're starting to see benefit for patients across the spectrum. [00:11:25] Lindsey Dinneen: Wow, so, so this is a very highly targeted-- it's able to get right to the source, right, so that there, it kind of helps to-- like you mentioned, there are some cancers that are much harder to treat by just sort of your, well, more standard practices with chemotherapy. So can you explain a little bit more about how it works in terms of the delivery? [00:11:50] Shaun Bagai: Yeah, think about tumors like pancreatic cancer tumors as cities with freeways next to them with no off-ramps. And that's one of the biggest issues is that when we think about tumors in general, we think of a ball of blood vessels with a lot of tumor cells. So blood supply gets there, they feed the tumors, but it also creates a, you know, off ramps or a highway to the tumors where chemotherapy reaches. Other tumors like pancreatic tumors, glioblastoma or brain tumors, non-small cell lung cancer bile duct cancer, uterine tumors, many others, they don't have this large blood supply. So it's like there's a freeway going next to a tumor and the chemotherapy doesn't see that tumor. So the way we've developed our technology, it's a double balloon catheter based system, so it's minimally invasive. It goes in through the patient's leg artery. And the patients are-- it's not a full surgery. It's more of a minimally invasive, same day outpatient procedure where the device isolates blood flow next the tumor, and uses pressure to force the chemotherapy to leave the vascular system to then bathe and saturate the tumor with chemo. So again, if you think about that freeway without an off ramp, we basically are forcing and creating and finding these micro channels like an off ramp to actually access the tumor. And this is where all our patents lie as well. So we developed this whole new method and mechanism of delivery of drugs and chemotherapy. [00:13:07] Lindsey Dinneen: That is amazing. So I'm sure that there are probably many stories as you've done this and just throughout your whole career. But are there any moments that really stand out to you as kind of affirming for you that, "Wow, I am in the right industry at the right time." [00:13:26] Shaun Bagai: I, I've luckily been validated with that thought process my whole career. As as a son of Indian parents, many say, "How did you not go to med school once you got in? Were you a disappointment to your family? Do you regret not gonna medical school and becoming a physician?" And I've been very lucky that I spent my whole career successfully helping technologies treat patients. The first moment was my first job going from declining med school through running clinical research and being the lead physician proctor, I used to fly around the country and teach doctors how to open up leg arteries that otherwise would be amputated. And by with this new technology, it was great to see how great patients were doing because of our technology. And every company I've worked on since has had that same effect on patients. So luckily, it's been always along the way, and very luckily, it was very early in my career to validate this this was the right pathway. [00:14:13] Lindsey Dinneen: Yeah. You know what you've mentioned too at the beginning that it sounds like a huge passion of yours, and maybe it has always been the case, but is making a difference in people's lives, being a part of companies that are, you know, actively improving and helping save lives. And so, I'm curious too, where did that passion come from? Was that part of that sort of, "I'm gonna be a physician, I'm gonna, you know, I'm gonna do this whole thing, I'm gonna save the athletes," but then, you know, kind of evolved from there? Or is that more deep seated? [00:14:46] Shaun Bagai: You know, it's interesting, I think it evolved along the way. I've always tried to be a helpful person in general, just as a human being. The, again, the, I think the initial idea was I wanna help patients because they couldn't help me as an athlete. So orthopedic surgery or cardiology were kind of the two i ideas or areas I wanted to specialize in when I thought the med school route. And then it was a matter of, I love the science, I love the technology, I love the medical science as well, and I love the business aspect of it. So I learned that there's this whole industry called medical technology that allows you to do all of that. And after seeing the benefit to our patients as a young clinical researcher, I really got the the addiction to trying to find ways to treat patients better. [00:15:29] Lindsey Dinneen: Yeah. Well, and I think I'd be curious to know too, 'cause I think, you know, that passion also comes from probably some core values that you hold that have sort of guided you. And I would wonder too is with, as having had such a diverse amount of really cool industry experience, what are some things that have been the guiding lights as you've gone around, you know, just things that you come back to as core values for how you wanna show up in the world? [00:15:59] Shaun Bagai: It's a very interesting question. I think one of the most interesting books that I have opportunity to be exposed to is "True North" and it's basically CEO's paths on aligning values with the company values and goals and making sure that that what you're doing is the right way to do things and the right thing to do. Often people can misstep as leaders in taking shortcuts and how you treat people. And there are no shortcuts. It's the hard work, it's the lead by example. It's putting in the late hours and demonstrating this is how you get things done. So I think that's probably a biggest part of making sure you align well with the company goals and having those values in place. And also how you treat people. We have a lot of leaders who are not the nicest people to their employees. I'm not gonna name any current companies, but, we all hear stories, they all exist. And I find that back to the, one of the original ideas is that when you align yourself and when you actually care about the people you work with and like the people you work with, they work harder and you work better as a team. And at the end of the day, all of us who work hard spend more time working than with our families and loved ones. And you want to actually make that fun and challenging and interesting and successful and it's almost like a second family, the people you work with. And it's important to keep that in mind 'cause people lose that a little bit. [00:17:12] Lindsey Dinneen: Yeah. Well, and I wanna go back to something you said too because this is actually a timely, interesting topic because of something that recently happened that I heard, and, you know, basically it was this idea of, if the personal goals aren't aligned with the company goals, they're not really worthwhile. And I was really struck by that comment and I was surprised by it because I don't feel that is true. Basically, to your point, part of it is you are spending, you're a hard worker, right? And so you're motivated to come in, you know you're doing things that matter. So it makes sense that you're going to have sort of, what would we call it, sort of innate personal goals that would hopefully align with the company's goals? But I'm curious, as a leader yourself, when you're helping your team maybe even develop or nurture those kinds of personal goals, how do you help them succeed both, you know, personally and professionally themselves, but then for the company so that as a whole, we are successful? [00:18:13] Shaun Bagai: I, I believe honestly, that's easier to do in a smaller startup type company than the large organizations. And the reason is because people who choose these types of companies have really strived to learn and grow, be exposed to, they're passionate about what they're doing 'cause it is so hard to be successful and there's always risk. And so I feel like building, running, working with and for companies that are kind of in a growth smaller phase, it almost weeds out the wrong types of people in terms of their ability to be passionate and work hard enough for that common goal. Because pretty quickly, and I've heard this before, and we've gone through this with our own companies, "This is too much work." And I've got someone else who was working 90 hours a week because they were so passionate about what we're doing with patients and they were touched by cancer. We've had cancer patients in the company, we've had family members with the cancer, so I feel like by nature you almost weed out the people that aren't the right fits. And there's also personal goals, and you know, people always have selfish motives at the core in certain areas, but being in a small company, you can identify where someone like to grow. And being in a small company, everyone does everything. In large siloed companies, you kind of miss that. And some people like that. They like the control, they like the punch and punch out, which is great. But when you're trying to build a small organization that's growing and pivoting and shifting, people like that fast-paced environment, and that's how I got lucky in how I grew. I got to do everything as a young, you know, post undergrad where I did clinical research and clinic, preclinical research and marketing and a little bit of sales and physician training, and that really allowed me to spread my wings and everyone I've mentored and guided and worked with feels the same way. [00:19:48] Lindsey Dinneen: Yeah. Yeah. I love that perspective. I think you touched on something that's really key is the alignment of goals in the sense of, we all know we're striving towards the same things, like we all want our patients to be healthier and live longer, better lives, you know, or what, whatever the mission statement is, per se, but being aligned and having that shared passion makes such a difference. So, okay, pivoting the conversation a little bit, just for fun. Imagine that you were to be offered a million dollars to teach a masterclass on anything you want. It can be within your industry, but it doesn't have to be. What would you choose to teach? [00:20:28] Shaun Bagai: You know, it's I used to think about that question when I was younger and thought "I have no talents." [00:20:31] Lindsey Dinneen: Oh, no. [00:20:33] Shaun Bagai: Yeah. But I've learned over the years that the things that make me successful are the ones that you don't think about. At least I didn't think about forefront. I think networking is probably the biggest piece, is really thinking about people who can have a positive impact and influence, and keeping in touch and not judging people, not dismissing people, not holding grudges. And you find along the years that you end up collecting a lot of interesting people that could be helpful for you down the road or you could help connect them. So I like connecting other people who can help people. And it's amazing. Throughout my career, I come back and I remember a fellow in Germany, I worked with my first company and he was in town for a conference. Fast forward 15 years, I'm like, "Hey, Dr. Naber, I'm in town. Why don't we meet? What are you up to these days?" "Oh, I'm working with this company called HeartFlow, and we have a new medical technology on looking at coronary artery disease. What are you up to?" "Oh, I'm the head of the hospital system in Frankfurt." It's like, wow, a lot's changed in 15 years and all of a sudden he became one of our biggest investigators and it's, and it wasn't because I thought I'd get something out of him. It's just I like keeping in touch with people and who knows where your path cross, and I've been able to connect other people to other people in the same regard. So, I remember I gave a talk about nine years ago on, on how I got to become a CEO of this company and I had this kind of Brady Bunch PowerPoint presentation. "Well, this person got me a job as an intern at this company. I met this doctor here. I met this company there," and there was like this spider web of how I got here. And it's amazing how all these people had an impact on my life at some point or another. And a lot of my team members are the same thing. It's amazing how many people you end up knowing if you're friendly, nice nonjudgmental, don't hold grudges, and people learn, grow, mature, change careers, and it's good to really treat everyone well and it comes back. [00:22:12] Lindsey Dinneen: Yeah. Could not agree more, and oh my goodness, I was just thinking about, yeah the, also the fact that, you know, as, as large as the industry is, it actually is also very small, so people know each other and so you also need to be cognizant of that as you're interacting. But I'm curious, just real follow real quick follow up to your point, what would be your advice for somebody who feels a little bit, maybe awkward or they're introverted, so it's a little bit harder to start those conversations. What would be a piece of advice for somebody who might either be new to networking or just not be comfortable with it very much? [00:22:52] Shaun Bagai: It is interesting 'cause I've been an extrovert mostly, but I'm also shy, which is oxymoronic. And I've got team members who have no problem walking up to, let's say a famous CEO or person and saying, "Hey, I'm i've got a question for you." And I think it's a matter of trying to break outta your comfort zone and ask questions because I find that most leaders do like to give back and do like to mentor. And a lot of them are very intelligent and a lot of 'em think a lot of themselves. And people like to talk and to teach. So, and that's more often the case than not. So for someone a little bit shy or trying to break into that idea is finding the right mentors and asking questions. People like to talk usually. And using that and being confident there, and also understanding that you may get blown off. You may get a no, you may get, you know, and not being disgruntled and going after it again and again, even though it's, it's difficult sometimes, but just to push yourself forward and be out there. [00:23:47] Lindsey Dinneen: Curiosity and persistence. I like it. There you go. There we go. All right. And how do you wish to be remembered after you leave this world? [00:23:59] Shaun Bagai: You know, I think about one of my first mentors, Dr. Josh McElroy. He has made an impact on medicine-- yeah, get emotional when I think about it-- that's mentored so many young people and built so many technologies that helps patients, and leaving this world having an impact on medicine where I help build therapies and technologies that made an impact for generation lives to come is really important. [00:24:23] Lindsey Dinneen: Yeah. And that's a beautiful legacy. Yeah. All right. And then final question. What is one thing that makes you smile every time you see or think about it? [00:24:33] Shaun Bagai: You know, I think it's the comradery with my team at work. And it's interesting 'cause the best days I work, it doesn't matter what's happening. If we're aligned and we have the same mission and we are pushing for the same direction. When you have 10 people wrong go about in the same direction, it feels amazing. And that's something that I really enjoy. And of course, it's not gonna be like that every day, every minute. And the challenges are always big and there's always, especially with an intelligent senior staff, there's always disagreements and arguments. But being open-minded and aligning and they, we always come around and align, those are the things that really make me smile. [00:25:08] Lindsey Dinneen: Yeah. That's great. That's awesome. Well, this has been a fantastic conversation. I really appreciate your time and your insights. I really appreciate, especially you going a little bit deeper into, yeah, kind of, kind of the lessons learned and what makes you tick and your passion for this industry and your current role. And we're so honored to be making a donation on your behalf as a thank you for your time today to the American Society for the Prevention of Cruelty to Animals, which is dedicated to preventing animal cruelty in the United States. So thank you for choosing that organization to support and we just wish you continued success as you work to change lives for a better world. Shaun Bagai: Thanks for the opportunity, Lindsey. Lindsey Dinneen: Thank you also to our listeners for tuning in, and if your feeling is inspired as I am right now, I'd love it if you'd share this episode with a colleague or two and we'll catch you next time. [00:26:01] Dan Purvis: The Leading Difference is brought to you by Velentium Medical. Velentium Medical is a full service CDMO, serving medtech clients worldwide to securely design, manufacture, and test class two and class three medical devices. Velentium Medical's four units include research and development-- pairing electronic and mechanical design, embedded firmware, mobile app development, and cloud systems with the human factor studies and systems engineering necessary to streamline medical device regulatory approval; contract manufacturing-- building medical products at the prototype, clinical, and commercial levels in the US, as well as in low cost regions in 1345 certified and FDA registered Class VII clean rooms; cybersecurity-- generating the 12 cybersecurity design artifacts required for FDA submission; and automated test systems, assuring that every device produced is exactly the same as the device that was approved. Visit VelentiumMedical.com to explore how we can work together to change lives for a better world.

Episode 201 - Sexual Health After Cancer Treatment: A Practical Show-And-Tell GuideIn this practical workshop, we focus on sexual health after cancer. This is a hands-on, show-and-tell session, designed to normalise conversations about sexual health and offer realistic options for managing discomfort after cancer, whether you're navigating this alone or with a partner. We'll look at dilators, compare vibrators and get into the nitty-gritty of it all!You'll learn:What Genitourinary Syndrome of Menopause (GSM) is, and why it commonly occurs after cancer treatmentWhat practical, evidence-informed tools may help — including dilators, vibrators, sex toys and supportive pelvic aids. Dani and her guest expert Eleanor, will show you lots of options!When and how these tools can be used safely, and how to choose what might be right for youAs always, the focus is on choice, reassurance and empowerment, with no pressure and no one-size-fits-all solutions.Our expert is Eleanor Gardener from Pelvic Relief. You can find El here:https://pelvicrelief.co.uk/?srsltid=AfmBOopffFtQo419pC_DdXAL-7IYwjB487zJNSIyBqOqUHxfmzb91kdzConnect with us:For more information and resources visit our website: www.menopauseandcancer.org Or follow us on Instagram @menopause_and_cancerJoin our Facebook group: www.facebook.com/groups/menopauseandcancerchathub

AI for Prostate Cancer Treatment Planning  Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Wayne G. Brisbane, MD

In today's episode of Beating Cancer Daily, Saranne introduces a unique and powerful method to navigate cancer treatments easily. Drawing from her own experience of beating Stage IV cancer, Saranne explores the concept of using carefully curated music playlists to transition into and out of treatments. Inspired by an encounter at a Broadway show, she shares insights on creating personalized soundtracks to uplift the spirit, reduce stress, and reclaim a sense of normalcy. Join Saranne as she delves into this creative strategy and offers examples to help you craft your own therapeutic playlists. Get ready to immerse yourself in a blend of music, motivation, and heartfelt advice as we live our best days, beating cancer together daily.2025 People's Choice Podcast Awards Best Health Series FinalistRanked the Top 5 Best Cancer Podcasts by CancerCare News in 2024 & 2025,and #1 Rated Cancer Survivor Podcast by FeedSpot in 2024 to 2025. Beating Cancer Daily is listened to in 140 countries across 7 continents and features over 400 original daily episodes hosted by Stage IV survivor Saranne Rothberg. To learn more about Host Saranne Rothberg and The ComedyCures Foundation:https://www.comedycures.org/ To write to Saranne or a guest:https://www.comedycures.org/contact-8 To record a message to Saranne or a guest:https://www.speakpipe.com/BCD_Comments_Suggestions To sign up for the free Health Builder Series live on Zoom with Saranne and Jacqui, go to The ComedyCures Foundation's homepage:https://www.comedycures.org/ Please support the creation of more original episodes of Beating Cancer Daily and other free ComedyCures Foundation programs with a tax-deductible contribution:http://bit.ly/ComedyCuresDonate THANK YOU! Please tell a friend whom we may help, and please support us with a beautiful review. Have a blessed day! Saranne  

This episode of Moms of the Lou features Kristen Smith, owner of TotSpot Social in Clayton. She shares her journey in creating a family-friendly space for St. Louis parents. She talks about the success of their first year in business, including popular events like Tot Time, Tools & Tales, and Tot Toast. At TotSpot Social, Kristen goes above and beyond in making it easy for parents when they visit, providing amenities, snacks, and various times in availability for families. She shares the victories and challenges in being a “mompreneur” and expresses her gratitude for the support TotSpot Social has received from the local St. Louis community. Don't forget to sign up for St. Louis Mom's Winter Play Date series at TotSpot Social on January 22nd from 4:30-6:30pm!This podcast episode is sponsored by Siteman Cancer Center: National Leaders in Cancer Treatment & Research.Kristen Smith is the owner and founder of TotSpot Social, a thoughtfully designed playroom and event space created with both kids and parents in mind. She and her husband, Kevin, developed the concept while raising their two young boys. TotSpot Social features an open-concept layout that allows adults to socialize while keeping a close eye on their kids, along with a liquor license for birthday parties and happy-hour playtimes.  Reviewers consistently describe Kristen as exceptionally attentive, welcoming, and hands-on—known for going above and beyond to make every visit and celebration feel personal and stress-free. With a deep passion for supporting parents and St. Louis businesses, Kristen has grown TotSpot Social into a trusted community space.We hope you enjoyed this podcast episode! To learn more about Moms of the Lou you can go to stlouismom.com or follow us on Instagram and Facebook. You can listen to the podcast on Apple Podcast and Spotify. And don't forget to rate and review so more people can tune in! This episode was produced by the St. Louis Mom. It was recorded and edited by STL Bucketlist Studios in St. Louis, Missouri. 

In this episode, Dr. Eric Rovner addresses a common fear that men have about prostate cancer treatment: incontinence. Drawing on his clinical experience, Dr. Rovner explains that treatment does not automatically mean a lifetime of bladder leakage. In fact, only a small percentage of patients experience long-lasting symptoms. He discusses why temporary changes in bladder control can occur, what factors influence recovery and - most importantly - what men can do before and after treatment to reduce their risk and regain control. Our conversation offers clarity, reassurance and actionable guidance for men navigating prostate cancer care. For more information about the National Association for Continence, click here, and be sure to follow us on Facebook, Instagram and Pinterest.Music:Rainbows Kevin MacLeod (incompetech.com)Licensed under Creative Commons: By Attribution 3.0 Licensehttp://creativecommons.org/licenses/by/3.0/Have you ever leaked when you sneeze, laugh or exercise and wondered, is this normal now? If so, you're not alone. That's why Virginia Mason, the Urology Care Foundation and NAFC have created a new podcast series called Pelvic Floor Power - to give you the insights you need to manage and overcome your condition. Listen here or wherever you get your podcasts.

As Barry Manilow's recent lung cancer diagnosis reminded us, a persistent cough, chest pain, shortness of breath may be more than just annoying symptoms. In this episode, we explain the signs you shouldn't ignore, what testing and treatment may look like, and how hope is still part of the story.  https://bit.ly/4szFIiaIn this Episode:02:21 - Tips for Longevity from People in their 90's - Naomi Rose & Physical Fitness04:48 - Avocado Salsa: Marriage of Guacamole and Pico de Gallo05:47 - Barry Manilow's Lung Cancer Diagnosis07:05 - Review of Lung Anatomy, Lung Cancer Overview, Differences between NSCLC and SCLC 09:32 - What Increases Our Risk of Lung Cancer?10:35 - Lung Cancer Signs and Symptoms to Watch For12:49 - Treatment of Lung Cancer - Reasons for Hope15:46 - Cancer Survivorship: How to Lower Your Risk of Cancer Returning and Signs not to Ignore18:57 - Discussion with Charlie: Historical Smoking, Persistent Cough24:04 - 27 y.o. Alexa Bekkerus Self-Written Obituary - How She Found Peace Dying with Metastatic Breast Cancer29:21 - OutroSupport the showGet show notes and resources at our website: every1dies.org. Facebook | Instagram | YouTube | mail@every1dies.org

In this episode, Dr. Sanda Moldovan interviews Katrina Faux, a functional practitioner who healed her breast cancer naturally. They discuss the increasing rates of breast cancer, the importance of holistic approaches, and the role of emotional trauma in cancer development. Katrina shares her personal journey, the detoxification process, and the impact of mold and heavy metals on health. They also explore the significance of functional testing, dietary approaches, and the connection between oral health and cancer. Katrina emphasizes the need for empowerment and education for clients dealing with cancer, and she offers resources for prevention and healing. Want to see more of The Holistic Dentistry Show? Watch our episodes on YouTube! Do you have a mouth- or body-related question for Dr. Sanda? Send her a message on Instagram! Remember, you're not healthy until your mouth is healthy. So take care of it in the most natural way.  Key Takeaways: Chapters (00:00) Introduction and Personal Updates (02:59) Katrina's Journey with Breast Cancer (05:53) The Role of Emotional Trauma in Cancer (08:51) Deciding on Natural Healing Methods (11:49) Detoxification and Its Importance (14:37) Navigating Heavy Metals and Mold Exposure (17:52) Monitoring Health Post-Remission (20:50) Helping Others Through Their Cancer Journeys (23:51) Innovative Screening and Prevention Techniques (27:45) The Role of Oral Health in Cancer (29:52) Detoxification Strategies for Cancer Patients (32:52) Dietary Approaches to Cancer Treatment (35:28) Challenges in Alternative Cancer Treatments (37:47) Proactive Measures for Cancer Prevention (40:20) Resources for Cancer Patients Guest Info: Instagram: https://www.instagram.com/katrinafoe/ YouTube: https://www.youtube.com/@cancerfreedom Facebook: https://www.facebook.com/nutritional.pilates Connect With Us:  AskDrSanda | YouTube BeverlyHillsDentalHealth.com | Instagram  DrSandaMoldovan.com | Instagram  Orasana.com | Instagram  

Send us a textIn this episode of WTR Small-Cap Spotlight, host Tim Gerdeman and analyst Robert Sassoon speak with Eric Poma PhD, CEO of Calidi Biotherapeutics Inc (NYSE American: CLDI).  The discussion focuses on how Calidi is solving the "delivery problem" in cancer treatment, and specifically how to transport cancer-killing oncolytic viruses systemically through the bloodstream without the body's immune system neutralizing them before they reach the tumor.

If you haven't heard of intratumoral bacteria, you may want to tune in because this could be the next big advancement when it comes to cancer treatment. On this show, Karolyn talks with one of her favorite guests, Dr. Tina Kaczor, who is a highly respected naturopathic oncologist who has devoted her professional career to helping people diagnosed with cancer. Dr. Kaczor will describe what intratumoral bacteria is and how it can impact cancer development, progression, and treatment response.Five To Thrive Live is broadcast live Tuesdays at 7PM ET and Music on W4CS Radio – The Cancer Support Network (www.w4cy.com) part of Talk 4 Radio (www.talk4radio.com) on the Talk 4 Media Network (www.talk4media.com).Five To Thrive Live Podcast is also available on Talk 4 Media (www.talk4media.com), Talk 4 Podcasting (www.talk4podcasting.com), iHeartRadio, Amazon Music, Pandora, Spotify, Audible, and over 100 other podcast outlets.

Guest: Gregory Copley. King Charles III is demonstrating resilience by outworking other royals and returning to full duties despite his ongoing cancer treatment, while steadfastly ignoring the distraction of gossip surrounding Prince Harry and Prince Andrew. The King faces a challenging year managing a relationship with Prime Minister Keir Starmer, whose government Copley describes as hostile to the monarchy and struggling with a tattered economy and a severe illegal migration crisis.1828 BANK OF ENGLAND

The CHALLENGE trial found that a three-year, structured exercise program after chemotherapy for stage III colon cancer reduced the risk of the cancer coming back (recurrence risk) and also led to people living longer overall. Dr. Kerry Courneya, the lead researcher, thinks the results can be applied to people with other types of cancer, including breast cancer. Listen to the episode to hear Dr. Courneya explain: why the study asked people to exercise for three years why he thinks the results may spur insurance companies to cover exercise-related costs, like equipment and gym memberships the reasons why the results also could apply to people diagnosed with breast cancer

In this captivating episode host Myrna Young discusses a groundbreaking advancement in cancer treatment with Dr. Jeffrey Gross, founder of ReCelebrate. The episode dives deep into the innovative use of Natural Killer (NK) cells as a promising non-toxic alternative to chemotherapy and radiation. Dr. Gross, a renowned expert in regenerative medicine and immunotherapy, explains how NK cell-derived exosomes are reshaping cancer treatment by selectively targeting cancer cells without harming healthy tissue. This conversation promises to shed light on emerging cancer therapies that evoke hope and potential for more humane cancer treatments.With a strong focus on NK cell-derived exosomes, Dr. Gross elaborates on how these natural remedies can boost the immune system, effectively contributing to cancer prevention and management. The episode further explores how current advancements in regenerative medicine are becoming accessible and offer substantial benefits to patients undergoing or at risk of cancer, while possibly enriching the lives of those with genetic predispositions to cancer. This episode provides vital insights into the future of cancer treatment, marking a pivotal moment for patients seeking comprehensive care options that could potentially enhance longevity and overall well-being.Key Takeaways:Revolutionary Cancer Treatment: NK cell-derived exosomes represent a new frontier in cancer treatment, offering a targeted and non-toxic alternative to chemotherapy and radiation therapy.Selective Targeting: These NK exosomes can naturally identify and attack cancer cells while bypassing healthy cells, minimizing collateral damage.Broad Application: Suitable for a variety of cancers, including blood cancers like leukemia and lymphoma, offering diverse treatment possibilities.Preventative Potential: Beyond treatment, NK exosome therapy might reduce cancer recurrence risk and serve as a preventative measure for high-risk patients.Evolving Alternative Medicine: Reflective of the broader trends in regenerative medicine, Dr. Gross and ReCelebrate are at the forefront of offering innovative therapies that prioritize patient well-being with fewer side effects.Notable Quotes:To advertise on our podcast, visit https://advertising.libsyn.com/TransformyourMindor email kriti@youngandprofiting.com See this video on The Transform Your Mind YouTube Channel https://www.youtube.com/@MyhelpsUs/videosTo see a transcripts of this audio as well as links to all the advertisers on the show page https://myhelps.us/Follow Transform Your Mind on Instagram https://www.instagram.com/myrnamyoung/Follow Transform Your mind on Facebookhttps://www.facebook.com/profile.php?id=100063738390977Please leave a rating and review on iTunes https://podcasts.apple.com/us/podcast/transform-your-mind/id1144973094 https://podcast.feedspot.com/personal_development_podcasts/

How Exercise Really Boosts Cancer Treatment Recovery with guest Scott Capozza January 4, 2026 Yale Cancer Center visit: https://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

How Exercise Really Boosts Cancer Treatment Recovery with guest Scott Capozza January 4, 2026 Yale Cancer Center visit: https://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

How do we find the "heart" of survivorship? In this 2025 recap of Navigating Cancer TOGETHER, we explore the most impactful cancer survivor stories of the year and share essential support for caregivers and patients. Host Talaya Dendy reflects on a landmark year for the show, providing a vulnerable 2025 cancer recap that balances professional milestones with her own personal 14-year health and survivorship journey.Whether you are navigating life after cancer or are currently in the thick of treatment, this episode offers a roadmap for the road ahead. We dive into the most-listened-to stories of the year, from prostate cancer awareness and men's health to the "Choosing Flat" movement and why these patient and survivor-led voices are the true heartbeat of the cancer community.Stop navigating alone. Join us!✨Episode Highlights:00:07:11 The Top Stories of 2025: Prostate Cancer Awareness & Choosing Flat00:10:17 Breaking the Silence: The Importance of Black Men's Voices in Cancer00:16:21 The 4:00 AM "Insomnia Club"00:24:23 Talaya's Favorite Moment: "What's at the Heart of Survivorship?00:32:14 14 Years NED & "Graduating" OncologyTranscript: https://bit.ly/podscript179Playlist: https://podcast.ausha.co/navigatingcancertogether/playlist/best-of-2025Connect & Engage with Talaya: https://solo.to/cancerdoula

Support the Institute today: https://givenow.nova.edu/the-institute-for-neuro-immune-medicine-inim-2025   In this episode, Dr. Matthew Halpert and Justin Taylor Hughes join Haylie Pomroy to discuss how immunotherapy can play a critical role in cancer treatment, particularly for patients who may not qualify for clinical trials. Dr. Halpert outlines the clinical process used to support and treat patients, provides an in-depth explanation of immunotherapy and its role in targeting cancer, and discusses the concept of correcting biological dysfunction through biological intervention. Justin shares his personal cancer journey, from exploring multiple treatment modalities to ultimately choosing a holistic and metabolic approach to his diagnosis. He also reflects on his experience with immunotherapy and the importance of spiritual and emotional support for himself and others navigating cancer. Dr. Matthew Halpert, a PhD graduate in Microbiology and Immunology from the University of Alabama at Birmingham (UAB), spent 10 years at Baylor College of Medicine as a leading Cancer Immunologist. His groundbreaking work in cancer immunotherapy has been widely published and cited over 450 times. Dr. Halpert founded Diakonos Oncology, pioneering Dendritic Cell Treatment, which is currently in FDA clinical trials, including a "Fast Track" Glioblastoma trial. In 2021, he established the Immunocine Cancer Center to provide immediate access to this innovative treatment for patients ineligible for trials.   Instagram: https://instagram.com/matthalpertphd https://instagram.com/immunocine Facebook - https://www.facebook.com/people/Matt-Halpert/100079347564008/ https://www.facebook.com/Immunocine X- https://x.com/Matthalpertphd https://x.com/ImmunocineCare LinkedIn: https://www.linkedin.com/in/matthew-halpert-b4695174/ https://www.linkedin.com/company/immunocine/ Website: https://immunocine.com   Justin Taylor Hughes, born in San Angelo and raised in Bulverde, Texas, is a cancer survivor, author, businessman, and founder of The United Creed, LLC. Diagnosed with cancer during the pandemic, Justin and his wife, Berphy, were supported by a diverse community and are dedicated to promoting unity in America through the principle of "Be Golden." Get Justin's book, "Be Golden" here. https://www.amazon.com/Be-Golden-Unity-Justin-Hughes-ebook/dp/B0CMJ85JB5   Learn more about the United Creed: Website: https://theunitedcreed.com/ Facebook: https://web.facebook.com/unitedcreed?_rdc=1&_rdr X: https://x.com/theunitedcreed Instagram: https://www.instagram.com/united_creed/ LinkedIn: https://www.linkedin.com/company/the-united-creed/ Haylie Pomroy, Founder and CEO of The Haylie Pomroy Group, is a leading health strategist specializing in metabolism, weight loss, and integrative wellness. With over 25 years of experience, she has worked with top medical institutions and high-profile clients, developing targeted programs and supplements rooted in the "Food is Medicine" philosophy. Inspired by her own autoimmune journey, she combines expertise in nutrition, biochemistry, and patient advocacy to help others reclaim their health. She is a New York Times bestselling author of The Fast Metabolism Diet.   Learn more about Haylie Pomroy's approach to wellness through her website: https://hayliepomroy.com   Instagram: https://www.instagram.com/hayliepomroy  Facebook: https://www.facebook.com/hayliepomroy  YouTube: https://www.youtube.com/@hayliepomroy/videos  LinkedIn: https://www.linkedin.com/in/hayliepomroy/  X: https://x.com/hayliepomroy    Enjoy our show? Please leave us a 5-star review on the following platforms so we can bring hope and help to others.   Apple Podcasts: https://podcasts.apple.com/us/podcast/hope-and-help-for-fatigue-chronic-illness/id1724900423   Spotify: https://open.spotify.com/show/154isuc02GnkPEPlWfdXMT   Sign up today for our newsletter. https://nova.us4.list-manage.com/subscribe?u=419072c88a85f355f15ab1257&id=5e03a4de7d   Enjoy our show? Please leave us a 5-star review on the following platforms so we can bring hope and help to others.   Apple Podcasts: https://podcasts.apple.com/us/podcast/hope-and-help-for-fatigue-chronic-illness/id1724900423   Spotify: https://open.spotify.com/show/154isuc02GnkPEPlWfdXMT   Sign up today for our newsletter. https://nova.us4.list-manage.com/subscribe?u=419072c88a85f355f15ab1257&id=5e03a4de7d   This podcast is brought to you by the Institute for Neuro-Immune Medicine. Learn more about us here.   Website: https://www.nova.edu/nim/ Facebook: https://www.facebook.com/InstituteForNeuroImmuneMedicine Instagram: https://www.instagram.com/NSU_INIM/ Twitter: https://www.twitter.com/NSU_INIM

In this Season One finale, host Talaya Dendy celebrates the milestone of completing The Healing Pen and a Mic Companion podcast. Reflecting on the live October workshop, Talaya shares why she has decided to keep her signature 5-hour "deep dive" format and how journaling serves as a vital tool for movement, not just reflection. This episode features moving testimonials from participants and a first look at the evolving future of the program for 2026 .Support Our Mission / Partner With Us:Bring Healing to Your Community: Interested in hosting The Healing Pen and a Mic workshop in your city or organization? We'd love to partner with you!Sponsor Future Workshops: Help us continue offering these much-needed, workshops to the cancer community.For partnership or sponsorship inquiries, please email us at nctpodcastfan@gmail.com.

Solid tumors represent one of the largest and most challenging areas in cancer treatment. In this interview, GT Biopharma (NASDAQ: GTBP) CEO Michael Breen explains why the company is expanding its platform into solid tumors and how its NK engager technology is designed to activate the body's natural immune response.Breen discusses the science behind GTB-5550, why B7H3 is a compelling target across many solid tumors, and how preclinical results support the company's next steps. He also outlines key milestones from 2025 and what investors should watch as GT Biopharma moves toward clinical trials and data readouts in 2026.Learn more about GT Biopharma: https://www.gtbiopharma.com/Watch the full YouTube interview here: https://www.youtube.com/watch?v=I7-Vd8PO8L0And follow us to stay updated: https://www.youtube.com/@GlobalOneMedia

CAR T therapy has delivered remarkable results for people with certain blood cancers—sometimes sending aggressive disease into deep remission after a single infusion. But today, only about 20% of eligible patients can actually get it. In this episode, sponsored by our partners at Allogene Therapeutics, Katie sits down with Dr. Zachary Roberts to unpack why access remains so limited and how new allogeneic (or “off-the-shelf”) CAR T therapies could be a turning point. They discuss how using healthy donor T-cells, rather than a patient’s own, may help bypass manufacturing hurdles and bring advanced treatment to more oncologists, more hospitals, and more communities. To learn more, visit Alpha3trial.com. #AllogenePartnerSee omnystudio.com/listener for privacy information.